التفاصيل البيبلوغرافية
| العنوان: |
Identification of Concomitant Inhibitors against Glutamine Synthetase and Isocitrate Lyase in Mycobacterium tuberculosis from Natural Sources. |
| المؤلفون: |
Chanda, Anesha, Kalita, Sanjib, Mishra, Awdhesh Kumar, Changkakoti, Liza, Sarma, Janayita Biswa, Biswas, Kunal, Kakati, Debashree, Mohanta, Yugal Kishore, Tanti, Bhaben, Mahanta, Saurov, Saravanan, Muthupandian |
| المصدر: |
BioMed Research International; 10/3/2022, Vol. 2022, p1-14, 14p |
| مصطلحات موضوعية: |
TUBERCULOSIS treatment, MEDICINAL plants, MYCOBACTERIUM tuberculosis, PLANT extracts, COMPUTER-assisted molecular modeling, GLUTAMINE, MOLECULAR structure, LIGANDS (Biochemistry) |
| مستخلص: |
Tuberculosis (T.B.) is a disease that occurs due to infection by the bacterium, Mycobacterium tuberculosis (Mtb), which is responsible for millions of deaths every year. Due to the emergence of multidrug and extensive drug-resistant Mtb strains, there is an urgent need to develop more powerful drugs for inclusion in the current tuberculosis treatment regime. In this study, 1778 molecules from four medicinal plants, Azadirachta indica, Camellia sinensis, Adhatoda vasica, and Ginkgo biloba, were selected and docked against two chosen drug targets, namely, Glutamine Synthetase (G.S.) and Isocitrate Lyase (I.C.L.). Molecular Docking was performed using the Glide module of the Schrӧdinger suite to identify the best-performing ligands; the complexes formed by the best-performing ligands were further investigated for their binding stability via Molecular Dynamics Simulation of 100 ns. The present study suggests that Azadiradione from Azadirachta indica possesses the potential to inhibit Glutamine Synthetase and Isocitrate Lyase of M. tuberculosis concomitantly. The excellent docking score of the ligand and the stability of receptor-ligand complexes, coupled with the complete pharmacokinetic profile of Azadiradione, support the proposal of the small molecule, Azadiradione as a novel antitubercular agent. Further, wet lab analysis of Azadiradione may lead to the possible discovery of a novel antitubercular drug. [ABSTRACT FROM AUTHOR] |
|
Copyright of BioMed Research International is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder